HYVET: Hypertension in the very elderly trial
HYVET showed that indapamide SR* ±perindopril treatment significantly reduced total mortality by 21% (P=0.019) and stroke mortality by 39% (P=0.046).
Furthermore, in patients receiving indapamide SR there were also relative risk reductions of 30% in stroke (P=0.055), of 64% in heart failure (P<0.001) and 34% in all cardiovascular events (P<0.001).
This means that one death would be avoided for every 40 patients treated with indapamide SR ±perindopril therapy for 2 years.
www.hyvet.com
Furthermore, in patients receiving indapamide SR there were also relative risk reductions of 30% in stroke (P=0.055), of 64% in heart failure (P<0.001) and 34% in all cardiovascular events (P<0.001).
This means that one death would be avoided for every 40 patients treated with indapamide SR ±perindopril therapy for 2 years.
www.hyvet.com
Labels: Cardiology, Nephrology
0 Comments:
Post a Comment
<< Home